CN115317656B - 一种含有胶原蛋白的医用敷料及制备方法 - Google Patents
一种含有胶原蛋白的医用敷料及制备方法 Download PDFInfo
- Publication number
- CN115317656B CN115317656B CN202211250239.5A CN202211250239A CN115317656B CN 115317656 B CN115317656 B CN 115317656B CN 202211250239 A CN202211250239 A CN 202211250239A CN 115317656 B CN115317656 B CN 115317656B
- Authority
- CN
- China
- Prior art keywords
- silicone oil
- collagen
- modified silicone
- tertiary amino
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 42
- 108010035532 Collagen Proteins 0.000 title claims abstract description 42
- 229920001436 collagen Polymers 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- -1 polysiloxane Polymers 0.000 claims abstract description 24
- 229920002545 silicone oil Polymers 0.000 claims abstract description 24
- 229940124530 sulfonamide Drugs 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920001971 elastomer Polymers 0.000 claims abstract description 21
- 239000000806 elastomer Substances 0.000 claims abstract description 21
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 claims abstract description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229920001296 polysiloxane Polymers 0.000 claims abstract description 15
- 150000003456 sulfonamides Chemical class 0.000 claims abstract description 14
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 6
- 125000001302 tertiary amino group Chemical group 0.000 claims description 20
- 229920013822 aminosilicone Polymers 0.000 claims description 18
- 239000003921 oil Substances 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- FSSPGSAQUIYDCN-UHFFFAOYSA-N 1,3-Propane sultone Chemical compound O=S1(=O)CCCO1 FSSPGSAQUIYDCN-UHFFFAOYSA-N 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 238000005266 casting Methods 0.000 claims description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 3
- 229920002379 silicone rubber Polymers 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 238000007664 blowing Methods 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 11
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 239000000758 substrate Substances 0.000 abstract description 5
- 230000003993 interaction Effects 0.000 abstract description 3
- 238000000053 physical method Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 7
- 231100000241 scar Toxicity 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002983 circular dichroism Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000512 collagen gel Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007731 hot pressing Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 101100073357 Streptomyces halstedii sch2 gene Proteins 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000011 protein activity measurement Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/04—Polysiloxanes
- C08G77/38—Polysiloxanes modified by chemical after-treatment
- C08G77/382—Polysiloxanes modified by chemical after-treatment containing atoms other than carbon, hydrogen, oxygen or silicon
- C08G77/392—Polysiloxanes modified by chemical after-treatment containing atoms other than carbon, hydrogen, oxygen or silicon containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/112—Phosphorus-containing compounds, e.g. phosphates, phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/208—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种含有胶原蛋白的医用敷料及制备方法,所述敷料包括以下组分:磺胺两性离子改性硅油、Ⅲ型重组人源胶原蛋白,磷钨酸,甘油,三乙醇胺和水。本发明以改性聚硅氧烷弹性体作为敷料基底,其采用物理方法进行交联,具有良好的力学性能的同时具有自愈合性,裂纹通过吸水、干燥后进行修复。利用磷钨酸与重组人源III型胶原蛋白的相互作用,达到缓释蛋白的作用,作用于伤口的时间长达48h,可持续稳定的释放胶原蛋白。
Description
技术领域
本发明属于合成生物医学材料技术领域,具体涉及一种含有胶原蛋白的医用敷料及制备方法。
背景技术
皮肤因手术、感染、烧烫伤等各种原因形成的瘢痕影响人体美观,可对患者的日常生活和社会活动造成严重影响。随着时代的发展和生活水平的提高,人们对瘢痕美化要求的越来越高,故各种成分的祛疤制剂如硅酮类凝胶、动物胶原蛋白凝胶和类人胶原蛋白凝胶等相继出现。重组人源Ⅲ型胶原蛋白功能凝胶是一种新型胶原蛋白,可以外源性地给予皮肤补充胶原蛋白,连接皮肤因创伤和感染造成的皮肤纤维断裂,抑制黑色素生成,抑制瘢痕,加速皮肤愈合。但以凝胶作为重组人源Ⅲ型胶原蛋白具有以下缺点:(1)凝胶成膜后力学强度低,在外力摩擦或水冲刷的作用下易流失,作用于伤口的时间较短、若未及时补充容易造成伤口干燥、感染、二次伤害;(2)保湿性较差,根据“湿性伤口愈合理论”,伤口在湿性无菌的环境下愈合情况更好;(3)不具有缓释性,持续稳定的释放重组人源Ⅲ型胶原蛋白能够避免I型胶原蛋白过度沉积或排列紊乱,从而避免病理性于瘢痕的产生。
发明内容
为了解决上述问题,本发明提供一种含有胶原蛋白的医用敷料,该敷料系由改性聚硅氧烷弹性体制成,具有良好的力学性能、抗菌性能和透气性,并且具有自愈合性,作用于伤口的时长可达48h,同时能够持续稳定的释放Ⅲ型胶原蛋白。
本发明的技术方案如下:
一种含有胶原蛋白的医用敷料,按质量百分比计算,包括以下组分:磺胺两性离子改性硅油、Ⅲ型重组人源胶原蛋白,磷钨酸,甘油,三乙醇胺和水。
本发明还提供上述含有胶原蛋白的医用敷料的制备方法,包括如下步骤:
(1)制备磺胺两性离子改性硅油
以无水乙醚为溶剂,N,N -二乙基胺丙基甲基二甲氧基硅烷在碱性条件下水解制备全接枝叔胺基硅油;进一步的,N,N -二乙基胺丙基甲基二甲氧基硅烷按计量比与八甲基环四硅氧烷D4和六甲基二硅氧烷MM混合,在氢氧化四甲铵硅醇盐的催化下,加热反应,制备得到叔胺基硅油;
以四氢呋喃为溶剂,叔胺基硅油与1,3-丙烷磺内酯(PS)在60℃下加热反应12h,然后进一步酸化后制备得到磺胺两性离子改性硅油。
(2)制备改性聚硅氧烷弹性体
分别用溶剂溶解磺胺两性离子改性硅油和磷钨酸,在加热条件下将两者混合,搅拌均匀后将获得的溶液浇铸到聚四氟乙烯模具中,室温下溶剂蒸发后,80℃真空干燥48h,得到改性聚硅氧烷弹性体。
(3)制备含有胶原蛋白的医用敷料
将步骤(2)得到的改性聚硅氧烷弹性体浸泡于含有胶原蛋白的药液中,时间为24h,随后捞出在20~30℃环境下吹风干燥,得到含有胶原蛋白的医用敷料。
进一步的,步骤(1)中叔胺基硅油的接枝率为20~50%。
进一步的,步骤(1)中叔胺基硅油的叔胺基摩尔量和1,3-丙烷磺内酯的摩尔量比例为1:1~2。
进一步的,步骤(2)中磺胺两性离子改性硅油与磷钨酸的质量比例为1:10~30%。
进一步的,步骤(2)中所述溶剂选自:水、甲醇、乙醇、异丙醇、乙腈中的一种或组合。
进一步的,步骤(3)中所述含有胶原蛋白的药液,具体组分如下:0.5~1%Ⅲ型重组人源胶原蛋白,3~4%甘油,三乙醇胺4~7%、余量为水。
有益效果:
(1)本发明以改性聚硅氧烷弹性体作为敷料基底,其采用物理方法进行交联,具有良好的力学性能的同时具有自愈合性,裂纹通过吸水、干燥后进行修复。另一方面,该敷料基底具有良好的吸水性和透明性,施加于伤口能够吸收渗出液、保持伤口湿润状态,同时可对伤口进行观察。
(2)本发明利用磺胺两性离子改性硅油上的季铵盐与磷钨酸通过静电作用力结合,同时发挥了季铵盐与磷钨酸的协同抗菌作用,防止伤口细菌、真菌感染。
(3)利用磷钨酸与重组人源III型胶原蛋白的相互作用,达到缓释蛋白的作用,作用于伤口的时间长达48h,可持续稳定的释放胶原蛋白。
(4)生物安全性实验表明,本发明的敷料皮肤刺激性和细胞毒性较小。
附图说明
图1为磺胺两性离子改性硅油的1H-NMR。
图2为测试例4胶原蛋白释放度随时间的变化关系。
图3为测试例4圆二色谱图。
具体实施方式
下面结合具体实施例对本发明做进一步详细说明,但实施例并不对本发明做任何形式的限定。除非特别说明,本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备。
实施例1
制备磺胺两性离子改性硅油。
(1)制备全接枝叔胺基硅油
以400mL无水乙醚溶解200g N,N -二乙基胺丙基甲基二甲氧基硅烷,搅拌升温至40℃缓慢滴加20wt% NaOH水溶液40 g,回流反应4 h后,将反应液倒入分液漏斗,水洗至pH≤8,取有机层用无水MgSO4干燥,过滤后挥发溶剂,得全接枝叔胺基硅油。
(2)制备部分接枝叔胺基硅油
往反应釜中加入全接枝叔胺基硅油,D4,MM和前述原料总质量1wt%的四甲基氢氧化铵,升温至90℃反应9h,然后升温至150℃继续搅拌30 min,得到粗产物在120℃下旋蒸5h除去小分子低沸物,得到部分接枝叔胺基硅油。
不同投料量下叔胺基硅油的接枝率和分子量如下表所示。
表1
样品 | 全接枝叔胺基硅油,g | D<sub>4</sub>,g | MM,g | Mn,g/mol | 接枝率1,% |
PAMS-1 | 58.34 | 55.22 | 2.62 | 6216 | 22.34% |
PAMS-2 | 74.26 | 23.17 | 2.37 | 5428 | 48.23% |
数均分子量(Mn)采用Waters 515-2414型凝胶渗透色谱仪测定,流动相为THF。
接枝率利用1H-NMR计算,计算方法如下:
叔胺基硅油的化学表达式为:
Si(CH3)3O[Si(CH3)2O]x[Si(CH3)(CH2CH2CH2N(C2H5)2]ySi(CH3)3
x和y分别对应重复单元数量,SMe对应Si-CH3在0~0.22ppm的出峰,SCH2对应Si-CH2在0.54ppm的出峰。
(3)制备磺胺两性离子改性硅油
将部分接枝叔胺基硅油和1,3-丙烷磺内酯用四氢呋喃溶解后装入圆底烧瓶中,于60℃水浴中加热反应12h,反应结束后反应液用过量的石油醚沉淀,重复三次后挥发溶剂,重新以去离子水或乙醇溶解,进行透析3d,干燥后的产物重新以乙醇溶解,加入35wt%盐酸调节pH=4进行加热回流酸化(40℃,6h),最后挥干溶剂得到磺胺两性离子改性硅油。
不同投料量下磺胺两性离子改性硅油的接枝率如下表所示。
表2
接枝率利用1H-NMR计算,计算方法如下:
磺胺两性离子改性硅油的分子结构表达式为:
SSCH2对应S-CH2在2.52ppm的出峰,SSiCH2对应Si-CH2在0.54ppm的出峰。
实施例2
制备改性聚硅氧烷弹性体。
以乙醇为溶剂分别溶解磺胺两性离子改性硅油和磷钨酸,浓度分别为0.5g/mL和0.2g/mL,在50℃下将两者混合,搅拌均匀后将获得的溶液浇铸到聚四氟乙烯模具中,室温下溶剂挥发后,80℃真空干燥48h,得到改性聚硅氧烷弹性体。
改性聚硅氧烷弹性体的投料量如下:
表3
测试例1
对改性聚硅氧烷弹性体进行吸水率(WU)测试,测试条件为常温、去离子水、浸泡时间为8h。
式中,mw和md分别为待测样品的湿重和干重。
测试例2
对改性聚硅氧烷弹性体进行力学性能测试。
采用热压的方式将弹性体制成条状,具体为100℃热压10min再冷压5min。样条尺寸:5cm×1cm×0.1~0.2cm。拉伸速率:500mm/min。
测试例3
对改性聚硅氧烷弹性体进行自愈合性能测试。
自愈合性能测试:以恒定作用力1N和恒定距离-0.1μm在样品表面划痕,然后在划痕表面滴加200μL的乙醇,使其铺开,放于常温鼓风箱中吹干,随后进行拉伸测试,以修复后的拉伸强度与原始拉伸强度的比值评价自修复率。
测试例1~3的结果如表4所示。
表4
样品 | WU,% | 拉伸强度,MPa | 断裂伸长率,% | 自修复率,% |
R1 | 31.2 | 5.48 | 128.5 | 84.3 |
R2 | 30.1 | 5.12 | 142.3 | 89.5 |
R3 | 47.5 | 7.21 | 89.7 | 77.1 |
R4 | 48.2 | 5.88 | 136.5 | 93.3 |
实施例3
制备改性聚硅氧烷弹性体并浸泡药液得到敷料,同时计算蛋白负载量。
S1:制备改性聚硅氧烷弹性,配方如下表5所示。
表5
S2:采用BCA法建立胶原蛋白含量标准曲线(pH7.4 PBS),测得A=0.45C+0.0071,r=0.9921。
S3:采用容量瓶精确配置以下配方药液5mL:0.5%Ⅲ型重组人源胶原蛋白,3%甘油,三乙醇胺4%、余量为水,取1mL放入石英比色皿中,测的吸光度OD1,及其对应的浓度c1(mg/mL)。
S4:称量已干燥至恒重的弹性体(规格0.5×0.5×0.12~0.15cm)为md,浸入S2中含有药液的比色皿,24h后用镊子取出,并加入去离子水将比色皿的溶液补充至1mL,测得吸光度OD2,及其对应的浓度c2(mg/mL)。
表6:蛋白负载量
从表6数据中可以看出,随着弹性体中磷钨酸的比例增加,敷料的蛋白负载量先减少后增大,这是由于随着磷钨酸投料量增大,弹性体的交联密度增大,从而导致吸水量减少,分子链联系得越紧密,蛋白难以扩散至敷料内部,但随着磷钨酸量进一步增大,由于磷钨酸表面有大量的氢键位点,与蛋白的羟基等发生相互作用,从而有利于蛋白的扩散。
测试例4
对实施例3制备得到的敷料(取出后放入30℃鼓风箱中吹干)进行体外释放度及蛋白活性测定。
将实施例3得到的敷料放入pH=7.4的 PBS溶液中,37℃下以100rpm的速度搅拌,一定的时间间隔取溶液使用BCA法测定其吸光度,同时补充等量PBS溶液,并计算体外释放度。
胶原蛋白释放度随时间的变化关系,参阅附图2。
对浸出液采用圆二色谱对比色皿中的蛋白溶液进行活性鉴定,具体方法如下:不同样品采用相近浓度(通过吸光度进行判断)的浸出液进行测试,同时配置相近浓度的重组胶原蛋白PBS溶液作为对照(本测试蛋白浓度为0.22±0.17mg/mL);对浸出液或对照组进行远紫外CD扫描,应用dicroprot软件对色谱图进行分析得到二级结构的信息。
圆二色谱图参阅附图3,浸出液蛋白二级结构含量如表7所示。
表7
在192nm、208对应的是-螺旋片段的构像,在195、216对应-折叠片段的构像。在200nm有较弱负吸收峰为无规则卷曲片段;205nm 为β-转角片段的构像。胶原蛋白在变性过程中会伴随着各个构像的含量变化,未变性胶原蛋白多肽链中-螺旋结构含量在50%以上。
测试例5
对敷料进行抑菌活性测试:将弹性体消毒后裁剪成直径15mm的圆片,放置在装有固体培养基的培养皿中央。用移液枪吸取20μL菌液(分别为:大肠杆菌、白色葡萄球菌和白色念珠菌,浓度均为1×109CFU/mL)涂布于圆片上。将培养基置于37℃培养箱中培养24h后取出,在无菌条件下移除圆片后利用打孔器取出圆片正下方直径为10mm的固体培养基,置于离心管中,并加入2000μL PBS缓冲液,超声4min后得到原菌液。将原菌液分别稀释104倍得到稀释液,分别取150μL各浓度稀释液涂布在装有固体培养基的培养皿中。将其置于37℃培养箱中培养24h后取出,观察并计数菌落数n,得出相应稀释液中细菌或真菌的个数,并按稀释倍数D推算出原菌液(2000μL)中细菌或真菌的个数N,计算公式如下:
测试例6
对敷料进行生物相容性测试:包括溶血实验和细胞毒性实验。
溶血实验:取新鲜含有枸橼酸钠抗凝剂的人血,按人血/生理盐水=5/4(w/w)的比例稀释,得到新鲜稀释抗凝人血。弹性体裁剪为约0.5×2×0.13cm样条,消毒后并放入试管中,并向其中加入2 mL生理盐水。取一支试管为阴性对照,向其中加入2 mL生理盐水,另取一支试管为阳性对照,向其中加入2mL蒸馏水。然后将所有试管放入37℃恒温水浴中保温30min,再向试管中加入2 mL混匀的新鲜稀释抗凝人血,轻轻混匀,置于37℃水浴中继续保温60 min。将试管中液体移入离心管中,在3000rpm速率下离心5 min,吸取上层清液,利用SMA5000型微量紫外光度计测试其在545 nm处吸光度,按以下公式计算溶血率:
式中,DS为测试样品的吸光度值,Dpc为阳性对照的吸光度,Dnc为阴性对照的吸光度。
细胞毒性测试:将消毒后的弹性体(1g)浸入10mLRPMI 1640培养基中24 h,并用RPMI 1640培养基稀释至原始浓度的50%。将L929细胞(鼠非整倍体纤维肉瘤细胞)在96孔培养板上以1.0×105细胞/mL的密度用上述RPMI 1640培养基进行培养。将细胞在37℃、CO2浓度为5 %的培养箱中培养过夜。细胞培养24h后,向孔中加入5.0 mg/mL浓度的MTT(PBS溶液),再在37℃下培养4 h。随后去除培养基,加入150μLDMSO,然后剧烈震动以溶解形成的紫色甲瓒晶体。用Wellscan Mk 3酶标仪在570 nm的波长下测量吸光度。
表8:测试例5~6结果
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (2)
1.一种含有胶原蛋白的医用敷料,其特征在于,包括以下组分:磺胺两性离子改性硅油、Ⅲ型重组人源胶原蛋白,磷钨酸,甘油,三乙醇胺和水;
所述的含有胶原蛋白的医用敷料的制备方法,包括如下步骤:
(1)制备磺胺两性离子改性硅油
以无水乙醚为溶剂,N,N -二乙基胺丙基甲基二甲氧基硅烷在碱性条件下水解制备全接枝叔胺基硅油;然后N,N -二乙基胺丙基甲基二甲氧基硅烷按计量比与八甲基环四硅氧烷D4和六甲基二硅氧烷MM混合,在氢氧化四甲铵硅醇盐的催化下,加热反应,制备得到部分接枝叔胺基硅油;
以四氢呋喃为溶剂,部分接枝叔胺基硅油与1,3-丙烷磺内酯在60℃下加热反应12h,然后酸化后制备得到磺胺两性离子改性硅油;
(2)制备改性聚硅氧烷弹性体
分别用溶剂溶解磺胺两性离子改性硅油和磷钨酸,在加热条件下将两者混合,搅拌均匀后将获得的溶液浇铸到聚四氟乙烯模具中,室温下溶剂蒸发后,80℃真空干燥48h,得到改性聚硅氧烷弹性体;
(3)制备含有胶原蛋白的医用敷料
将步骤(2)得到的改性聚硅氧烷弹性体浸泡于含有胶原蛋白的药液中,时间为24h,随后捞出在20~30℃环境下吹风干燥,得到含有胶原蛋白的医用敷料;
所述步骤(1)中部分接枝叔胺基硅油的接枝率为20~50%;
所述步骤(1)中部分接枝叔胺基硅油的叔胺基摩尔量和1,3-丙烷磺内酯的摩尔量比例为1:1~2;
所述步骤(2)中磺胺两性离子改性硅油与磷钨酸的质量比例为1:10~30%;
所述步骤(3)中含有胶原蛋白的药液,具体组分如下:0.5~1%Ⅲ型重组人源胶原蛋白,3~4%甘油,三乙醇胺4~7%、余量为水。
2.根据权利要求1所述的一种含有胶原蛋白的医用敷料的制备方法,其特征在于,步骤(2)中所述溶剂选自:水、甲醇、乙醇、异丙醇、乙腈中的一种或组合。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211250239.5A CN115317656B (zh) | 2022-10-13 | 2022-10-13 | 一种含有胶原蛋白的医用敷料及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211250239.5A CN115317656B (zh) | 2022-10-13 | 2022-10-13 | 一种含有胶原蛋白的医用敷料及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115317656A CN115317656A (zh) | 2022-11-11 |
CN115317656B true CN115317656B (zh) | 2022-12-27 |
Family
ID=83915090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211250239.5A Active CN115317656B (zh) | 2022-10-13 | 2022-10-13 | 一种含有胶原蛋白的医用敷料及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115317656B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115779140B (zh) * | 2023-02-09 | 2023-05-02 | 江苏亨瑞生物医药科技有限公司 | 含有胶原蛋白的伤口敷料及制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110938207B (zh) * | 2019-12-10 | 2022-02-22 | 烟台开发区金宏化工有限公司 | 一种含氢硅油的制备方法 |
CN113117137A (zh) * | 2021-04-20 | 2021-07-16 | 山东慕驰生物医药科技有限公司 | 一种含有重组人源胶原蛋白的医用敷料及制备方法 |
-
2022
- 2022-10-13 CN CN202211250239.5A patent/CN115317656B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN115317656A (zh) | 2022-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yong et al. | Conformal hydrogel coatings on catheters to reduce biofouling | |
CN115317656B (zh) | 一种含有胶原蛋白的医用敷料及制备方法 | |
CN108484936B (zh) | 一种接枝改性材料所制备的水凝胶及其制备方法和应用 | |
CN111166931A (zh) | 一种甲基丙烯酸丝胶/壳聚糖季铵盐水凝胶及其制备方法和应用 | |
CN113174060A (zh) | 一种海藻酸-壳寡糖-氧化锌复合水凝胶及其制备方法和应用 | |
CN115252888B (zh) | 一种胶原蛋白凝胶敷料及其制备方法和应用 | |
CN114392388A (zh) | 一种水凝胶组合物及其应用 | |
CN119258263B (zh) | 负载外泌体水凝胶制备方法、负载外泌体水凝胶及用途 | |
CN118217445A (zh) | 可用于皮肤伤口修复的复合水凝胶及其制备方法和应用 | |
Chen et al. | Photothermal Nanozyme‐Encapsulating Microneedles for Synergistic Treatment of Infected Wounds | |
Ghomi et al. | Biomimetic aligned nanofibrous dressings containing cell-selective polymer enhance diabetic wound regeneration | |
CN102675674A (zh) | 一种溶菌酶与香菇多糖硫酸酯自组装修饰的聚乳酸材料及其制备方法 | |
CN101987887B (zh) | 一种改性硅橡胶及其改性方法和用途 | |
WO2016090892A1 (zh) | 一种治疗糖尿病足的水溶性凝胶 | |
CN119139487A (zh) | 一种蛋白纳米硒水凝胶在制备防治银屑病药物中的用途 | |
Wei et al. | Facile preparation of carboxymethyl chitosan/dextran/poly (ionic liquid)-based hydrogel with intrinsic antibacterial and antioxidant properties for accelerating skin wound healing | |
CN105727360A (zh) | 用于手术皮肤切口、感染性和非感染性创面的生物材料及其应用 | |
Guo et al. | Bacterial-responsive biodegradable silver nanoclusters composite hydrogel for infected wound therapy | |
CN118026159A (zh) | 一种石墨烯的改性方法 | |
CN118121752A (zh) | 一种抗炎抑菌的dstq水凝胶及其制备方法和应用 | |
Fan et al. | KGRT peptide incorporated hydrogel with antibacterial activity for wound healing by optimizing cellular functions via ERK/eNOS signaling | |
CN111234163B (zh) | 一种兼具抗菌修复性能的纳米凝胶及其制备方法与应用 | |
Hao et al. | Enzyme-mediated multifunctional self-healing lysozyme hydrogel for synergistic treatment of chronic diabetic wounds | |
CN117045856B (zh) | 多功能自愈合可注射水凝胶及其制备方法与应用 | |
CN115779140B (zh) | 含有胶原蛋白的伤口敷料及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |